CD20
CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.
All Product Categories
-
CD20 Related Products (50)
Related Products (50)
-
Antibodies (1)
-
BI-1206
0 ImagesCat. No.: HY-P991225BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
-
Ripertamab
0 ImagesSynonyms: SCT400Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy.
-
Divozilimab
0 ImagesSynonyms: BCD-132Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
-
Amulirafusp alfa
0 ImagesSynonyms: IMM-0306Amulirafusp alfa (IMM-0306) is a fusion protein of CD20 monoclonal antibody (mAb) with the CD47 binding domain of SIRPα, with human CD20 Kd 2.45 nM and human CD47 Kd 4.91 nM. Amulirafusp alfa binds to CD20 and CD47 on B cells, engages FcɣR, blocks CD47-SIRPα interaction, activates macrophages, NK cells, and complement cascade, mediates phagocytosis and cytotoxicity, inhibits apoptosis of Jurkat-CSR cells, reverses IL-16 tumor-promoting effects, and binds human/cynomolgus CD47 but not mouse/rat CD47. Amulirafusp alfa can be used for the research of hematological malignancies, relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma, relapsed or refractory B-cell non-Hodgkin lymphoma, and activated B-cell-like diffuse large B-cell lymphoma.
-
Blidarvetug
0 ImagesBlidarvetug is a veterinary monoclonal antibody targeting MS4A1/CD20, which can be used to study CD20-positive B-cell lymphoma in dogs.
-
Eramkafusp Alfa
0 ImagesCat. No.: HY-P990054Synonyms: IGN-002
-
PF-5212374
0 ImagesCat. No.: HY-P990649CAS No.: 1169717-01-4Synonyms: TRU-015PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases.
-
Anti-Mouse CD20 Antibody (18B12)
0 ImagesCat. No.: HY-P992060Purity: 99.33%Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8+ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury.
-
Zemlikafusp alfa
0 ImagesCat. No.: HY-P992074Synonyms: IPH6501Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
-
AL044
0 ImagesCat. No.: HY-P991905AL044 is an antibody targeting MS4A family proteins. AL044 can mimic the protective effects of MS4A gene variants, thereby increasing the expression of both sTREM2 and membrane-bound TREM2 in cells. AL044 is applicable for research on Alzheimer's disease.
-
Zareprumig
0 ImagesCat. No.: HY-P992144CAS No.: 3062698-53-4Synonyms: RO-7121932Zareprumig is a human monoclonal antibody targeting CD20/MS4A1&CD71/TFRC.
-
Anafiltamig
0 ImagesCat. No.: HY-P991671CAS No.: 3009026-69-8Synonyms: JNJ-80948543Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
-
TRS-005
0 ImagesCat. No.: HY-185428Purity: 99.83%TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma).
-
Anti-CD20 Antibody (mAb 1.5.3)
0 ImagesCat. No.: HY-P991547CAS No.: 922534-56-3Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies.
-
Nofetumomab
0 ImagesCat. No.: HY-P992095
-
Imvotamab
0 ImagesCat. No.: HY-P99660CAS No.: 2573121-53-4Synonyms: IGM-2323Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
-
BLX-301
0 ImagesCat. No.: HY-P991548CAS No.: 2170268-76-3BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis.
-
DXL625
0 ImagesCat. No.: HY-P992349DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.
-
MIL62 (FUT8-KO)
0 ImagesCat. No.: HY-P991514AMIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody.
-
MEDI-552
0 ImagesCat. No.: HY-P991546MEDI-552 is a human IgG monoclonal antibody targeting CD20/membrane-spanning 4-domains subfamily A member 1 (MS4A1).
